<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02950870</url>
  </required_header>
  <id_info>
    <org_study_id>HCV_AMH_16</org_study_id>
    <nct_id>NCT02950870</nct_id>
  </id_info>
  <brief_title>Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.</brief_title>
  <official_title>An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Modena and Reggio Emilia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determinate the AMH levels before and after antiviral therapy
      with Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in comparison with age-matched
      HCV-positive women not undergoing antiviral treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is interventional, controlled randomized (block 2:1 case: controls) in open label.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The modification of AMH levels</measure>
    <time_frame>48 weeks post treatment</time_frame>
    <description>The primary outcome is to evaluate the modification of AMH levels before and after successful antiviral therapy in comparison with age-matched HCV-positive women not undergoing antiviral treatment is the primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modification of AMH levels</measure>
    <time_frame>144 weeks</time_frame>
    <description>Modification of AMH levels before and after successful antiviral therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of the Estradiol (E2) levels</measure>
    <time_frame>144 weeks</time_frame>
    <description>Modification of the Estradiol (E2) levels before and after successful antiviral therapy in comparison with age-matched HCV-positive women not undergoing antiviral treatment is the primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing miscarriage</measure>
    <time_frame>144 weeks</time_frame>
    <description>Percentage of participants experiencing miscarriage during 3 years observation post-therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Chronic Hepatitis, C Virus</condition>
  <arm_group>
    <arm_group_label>group treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this group will be treated with Ombitasvir-Paritaprevir-Ritonavir (12,5 mg/75 mg/50 mg) and Dasabuvir ( 250 mg) with or without Ribavirina every day , for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group untreated</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir-Paritaprevir-Ritonavir</intervention_name>
    <description>The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose</description>
    <arm_group_label>group treated</arm_group_label>
    <other_name>Viekirax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasabuvir</intervention_name>
    <description>The patient will be treated daily with Dasubavir 500 mg total dose</description>
    <arm_group_label>group treated</arm_group_label>
    <other_name>Exvieria</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Patients will be treated with ribavirin if necessary.</description>
    <arm_group_label>group treated</arm_group_label>
    <other_name>RBV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female between 18 and 35 years of age at the time of Screening

          -  Childbearing potential and sexually active with male partner(s) currently using at
             least one effective method of birth control at the time of screening and two effective
             methods of birth control while receiving study drugs, starting with Study Day 1 and
             for 7 months after stopping study drug.

          -  Females must have negative results for pregnancy tests

          -  Chronic HCV-infection prior to study enrollment

          -  Screening laboratory result indicating HCV GT 1b or GT 1a or GT 4 infection.

          -  Must be able to voluntarily sign and date an informed consent form

          -  Liver biopsy within 24 months prior to or during screening demonstrating a Metavir
             score of 2 or less or an Ishak score of 3 or less or Screening FibroScan® result of ≤
             9.6 kPa;

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Positive test result for HBsAg and HIV Ab

          -  Recent history of drug or alcohol

          -  HCV genotype performed during screening indicates more than 1 subtype or co-infection
             with any other genotype.

          -  Use of medications contraindicated

          -  Use of known strong inducers of cytochrome P450 3A (CYP3A) or strong inducers of
             cytochrome P450 2C8 (CYP2C8) or strong inhibitors of CYP2C8

          -  History of solid organ transplant.

          -  Confirmed presence of hepatocellular carcinoma

          -  Current use of any investigational or commercially available anti-HCV agents

          -  Screening laboratory analyses showing any of the following abnormal laboratory results
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ERICA VILLA, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ERICA VILLA, Prof.</last_name>
    <phone>+39 0594224359</phone>
    <email>erica.villa@unimore.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>VERONICA BERNABUCCI, MD.</last_name>
    <phone>+39 0594223109</phone>
    <email>veronica.bernabucci@libero.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gastroenterology Unit</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erica Villa, Prof.</last_name>
      <phone>+390594225308</phone>
      <email>erica.villa@unimore.it</email>
    </contact>
    <contact_backup>
      <last_name>VERONICA BERNABUCCI, MD</last_name>
      <phone>+390594223109</phone>
      <email>veronica.bernabucci@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Erica Villa, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Modena and Reggio Emilia</investigator_affiliation>
    <investigator_full_name>Prof. Facchinetti Fabio</investigator_full_name>
    <investigator_title>PRS administrator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

